CONDITION AND ENHANCE SYSTEM

Manufacturer: OMP, INC. | PURETEK CORPORATION | Ei INC. | Swiss-American Products | Bay Cities Container Corporation
Effective date: 2012-05-10
Label type: HUMAN PRESCRIPTION DRUG LABEL
Version: 1
Source: full-release
Hydrated at: 2026-05-31 20:15:12

Label at a glance#

ProductCONDITION AND ENHANCE SYSTEM TRAVEL-SIZE NON-SURGICAL

Active ingredientHYDROQUINONE, OCTINOXATE, ZINC OXIDE

Label structure12 sections

Indications and uses

The gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation.

Dosage and administration

A thin application should be applied to the affected area twice daily or as directed by a physician. If no improvement is seen after three (3) months of treatment, use of this product should be discontinued. Sun exposure should be limited by using a sunscreen agent, a sun blocking agent, or protective clothing to cover bleached skin when using and after using this product in order to prevent repigmentation.

Contacts and useful links#

PhoneLabel contact1-800-636-7546

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx Only
FOR EXTERNAL USE ONLY

DESCRIPTION

DESCRIPTION SECTION

Hydroquinone is 1,4-benzenediol. Hydroquinone occurs as fine, white needles. The drug is freely soluble in water and in alcohol. Chemically, hydroquinone is designated as p-dihydroxybenzene; the empirical formula is C₆ H₆ O₂; molecular weight is 110.0.

Obagi^® Condition & Enhance Blender contains Hydroquinone USP 40 mg/gm in a base of purified water, glycerin, cetyl alcohol, PPG-2 myristyl ether propionate, sodium lauryl sulfate, TEA-salicylate, lactic acid, phenyl trimethicone, tocopheryl acetate, sodium metabisulfite, ascorbic acid, methylparaben, saponins, disodium EDTA, BHT, and propylparaben.

Obagi^® Condition & Enhance Clear contains Hydroquinone USP 40 mg/gm in a base of purified water, cetyl alcohol, glycerin, sodium lauryl sulfate, stearyl alcohol, tocopheryl acetate, ascorbic acid, sodium metabisulfite, lactic acid, saponins, disodium EDTA, methylparaben, BHT, propylparaben, and butylparaben.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

SPL UNCLASSIFIED SECTION

Topical application of hydroquinone produces a reversible depigmentation of the skin by inhibition of the enzymatic oxidation of tyrosine to 3, 4-dihydroxyphenylalanine (dopa) and suppression of other melanocyte metabolic processes.

Exposure to sunlight or ultraviolet light will cause repigmentation of the bleached areas, which may be prevented by the use of sunblocking agents or sunscreen agents contained in Obagi Condition & Enhance.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

The gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Prior history of sensitivity or allergic reaction to this product or any of its ingredients. The safety of topical hydroquinone use during pregnancy or in children (12 years and under) has not been established.

WARNINGS

WARNINGS SECTION

Caution

SPL UNCLASSIFIED SECTION

Hydroquinone is a skin bleaching agent which may produce unwanted cosmetic effects if not used as directed. The physician should be familiar with the contents of this insert before prescribing or dispensing this medication.

Test for skin sensitivity before using by applying a small amount to an unbroken patch of skin and check in 24 hours. Minor redness is not a contraindication, but where there is itching or vesicle formation or excessive inflammatory response, further treatment is not advised. Close patient supervision is recommended.

Avoid contact with eyes. In case of accidental contact, patient should rinse eyes thoroughly with water and contact physician. A bitter taste and anesthetic effect may occur if applied to lips.

Sunscreen use is an essential aspect of hydroquinone therapy because even minimal sunlight exposure sustains melanocytic activity.

Warning

SPL UNCLASSIFIED SECTION

Contains sodium metabisulfite, a sulfite that may cause serious allergic type reactions (e.g., hives, itching, wheezing, anaphylaxis, severe asthma attacks) in certain susceptible persons.

PRECAUTIONS

PRECAUTIONS SECTION

(SEE WARNINGS)

General

GENERAL PRECAUTIONS SECTION

Treatment should be limited to relatively small areas of the body at one time since some patients experience a transient skin reddening and a mild burning sensation which does not preclude treatment.

Pregnancy Category C

PREGNANCY SECTION

Animal reproduction studies have not been conducted with topical hydroquinone. It is also not known whether hydroquinone can cause fetal harm when used topically on a pregnant woman or affect reproductive capacity. It is not known to what degree, if any, topical hydroquinone is absorbed systemically. Topical hydroquinone should be used on pregnant women only when clearly indicated.

Nursing mothers

NURSING MOTHERS SECTION

It is not known whether topical hydroquinone is absorbed or excreted in human milk. Caution is advised when topical hydroquinone is used by a nursing mother.

Pediatric usage

PEDIATRIC USE SECTION

Safety and effectiveness in children below the age of 12 years have not been established.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

No systemic adverse reactions have been reported. Occasional hypersensitivity (localized contact dermatitis) may occur, in which case the medication should be discontinued and the physician notified immediately.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

HOW SUPPLIED

HOW SUPPLIED SECTION

Obagi Condition and Enhance Blender is available as follows:

2 oz. (57 gm) bottle	NDC 62032-115-36
1 oz. (28.5 gm) bottle	NDC 62032-115-10

Obagi Condition and Enhance Clear is available as follows:

2 oz. (57 gm) bottle

NDC 62032-117-36

STORAGE AND HANDLING SECTION

Store at 25°C (77°F); excursion permitted to 15°C-30°C (59°F-86°F).

SPL UNCLASSIFIED SECTION

OBAGI^®
MEDICAL

OMP, Inc.
Long Beach, CA 90802
USA
1-800-636-7546
80707910U Rev. 6/07

PRINCIPAL DISPLAY PANEL - Kit Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

OBAGI^®
CONDITION & ENHANCE SYSTEM
For Use with Nonsurgical Procedures

Travel Size

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUI	RxNorm string	TTY	SPL version
197795	hydroquinone 4 % Topical Cream	PSN	1
197795	hydroquinone 40 MG/ML Topical Cream	SCD	1
197795	hydroquinone 4 % Topical Cream	SY	1

DailyMed Pharmacologic Classes#

Class, Version, Type table
Class	Version	Type	Effective
HYDROQUINONE Pharmacologic Class Indexing	2	Indexing - Pharmacologic Class	20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
f52be47f-7aa7-46c0-b1fa-50c18dd50206	Product name	1	20201029
444b3e50-f226-46ef-bfca-2e7035d140cd	Product name	1	20190611
7cda52fc-125f-421c-8fea-bc1974370c49	Product name	2	20180703
c5cd4727-ac49-4409-82b1-5bd8006c3ec7	Product name	1	20171122
597b1cfd-7b31-5048-62be-ca5cd740da2f	Product name	1	20140508
85490a6b-2306-6bf2-c51b-eb63537dc2da	Product name	1	20140508
ec2149b3-5c6d-5344-f757-c86411073075	Product name	1	20140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDC	Effective	Action	Document	Indexing SPL	Related label
62032-510-60	2019-11-13	C162847	48780-1	97449f38-d4b7-f6ea-e053-dbdaa90aa703	Obagi ® Condition & Enhance Clear (Hydroquinone USP, 4%) Skin Bleaching Cream Obagi ® Condition & Enhance Blender ® (Hydroquinone USP, 4%) Skin Bleaching Cream

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	Strength	SPL version
62032-115-10	CONDITION AND ENHANCE SYSTEM TRAVEL-SIZE NON-SURGICAL	28.5 g in 1 BOTTLE, PLASTIC	CREAM	28.5 g	40 mg in 1g	1
62032-117-36	CONDITION AND ENHANCE SYSTEM TRAVEL-SIZE NON-SURGICAL	57 g in 1 BOTTLE, PLASTIC	CREAM	57 g	40 mg in 1g	1
62032-119-10	CONDITION AND ENHANCE SYSTEM TRAVEL-SIZE NON-SURGICAL	30 mL in 1 BOTTLE, PLASTIC	CREAM	30 mL	90 mg in 1mL	1
62032-510-60	CONDITION AND ENHANCE SYSTEM TRAVEL-SIZE NON-SURGICAL	1 in 1 CARTON	KIT	1		1

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDC	Dashboard title	SPL version	Validation	Dashboard ZIP
62032-115	CONDITION AND ENHANCE SYSTEM TRAVEL-SIZE NON-SURGICAL (HYDROQUINONE, OCTINOXATE, AND ZINC OXIDE) KIT [OMP, INC.]	1	Legacy NDC	20120521_5d843214-4ede-4bd5-a919-c8faca9ccade.zip
62032-117	CONDITION AND ENHANCE SYSTEM TRAVEL-SIZE NON-SURGICAL (HYDROQUINONE, OCTINOXATE, AND ZINC OXIDE) KIT [OMP, INC.]	1	Legacy NDC	20120521_5d843214-4ede-4bd5-a919-c8faca9ccade.zip
62032-119	CONDITION AND ENHANCE SYSTEM TRAVEL-SIZE NON-SURGICAL (HYDROQUINONE, OCTINOXATE, AND ZINC OXIDE) KIT [OMP, INC.]	1	Legacy NDC	20120521_5d843214-4ede-4bd5-a919-c8faca9ccade.zip
62032-510	CONDITION AND ENHANCE SYSTEM TRAVEL-SIZE NON-SURGICAL (HYDROQUINONE, OCTINOXATE, AND ZINC OXIDE) KIT [OMP, INC.]	1	Legacy NDC, 4 package rows	20120521_5d843214-4ede-4bd5-a919-c8faca9ccade.zip

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	SPL version
HYDROQUINONE	ACTIVE INGREDIENT	XV74C1N1AE	1
OCTINOXATE	ACTIVE INGREDIENT	4Y5P7MUD51	1
ZINC OXIDE	ACTIVE INGREDIENT	SOI2LOH54Z	1
HYDROQUINONE	ACTIVE MOIETY	XV74C1N1AE	1
OCTINOXATE	ACTIVE MOIETY	4Y5P7MUD51	1
ZINC OXIDE	ACTIVE MOIETY	SOI2LOH54Z	1
ALPHA-TOCOPHEROL ACETATE	INACTIVE INGREDIENT	9E8X80D2L0	1
ASCORBIC ACID	INACTIVE INGREDIENT	PQ6CK8PD0R	1
BUTYLATED HYDROXYTOLUENE	INACTIVE INGREDIENT	1P9D0Z171K	1
BUTYLPARABEN	INACTIVE INGREDIENT	3QPI1U3FV8	1
C13-14 ISOPARAFFIN	INACTIVE INGREDIENT	E4F12ROE70	1
CETOSTEARYL ALCOHOL	INACTIVE INGREDIENT	2DMT128M1S	1
CETYL ALCOHOL	INACTIVE INGREDIENT	936JST6JCN	1
CITRIC ACID MONOHYDRATE	INACTIVE INGREDIENT	2968PHW8QP	1
DIETHANOLAMINE CETYL PHOSPHATE	INACTIVE INGREDIENT	4UG0316V9S	1
EDETATE DISODIUM	INACTIVE INGREDIENT	7FLD91C86K	1
ETHYLHEXYL STEARATE	INACTIVE INGREDIENT	EG3PA2K3K5	1
ETHYLPARABEN	INACTIVE INGREDIENT	14255EXE39	1
GLYCERIN	INACTIVE INGREDIENT	PDC6A3C0OX	1
ISOBUTYLPARABEN	INACTIVE INGREDIENT	0QQJ25X58G	1
ISOPROPYL PALMITATE	INACTIVE INGREDIENT	8CRQ2TH63M	1
LACTIC ACID	INACTIVE INGREDIENT	33X04XA5AT	1
LAURETH-7	INACTIVE INGREDIENT	Z95S6G8201	1
METHYLPARABEN	INACTIVE INGREDIENT	A2I8C7HI9T	1
PHENOXYETHANOL	INACTIVE INGREDIENT	HIE492ZZ3T	1
PHENYL TRIMETHICONE	INACTIVE INGREDIENT	DR0K5NOJ4R	1
POLYSORBATE 60	INACTIVE INGREDIENT	CAL22UVI4M	1
PPG-2 MYRISTYL ETHER PROPIONATE	INACTIVE INGREDIENT	88R97D8U8A	1
PROPYLPARABEN	INACTIVE INGREDIENT	Z8IX2SC1OH	1
SODIUM HYDROXIDE	INACTIVE INGREDIENT	55X04QC32I	1
SODIUM LAURYL SULFATE	INACTIVE INGREDIENT	368GB5141J	1
SODIUM METABISULFITE	INACTIVE INGREDIENT	4VON5FNS3C	1
STEARYL ALCOHOL	INACTIVE INGREDIENT	2KR89I4H1Y	1
TRIETHOXYCAPRYLYLSILANE	INACTIVE INGREDIENT	LDC331P08E	1
TROLAMINE SALICYLATE	INACTIVE INGREDIENT	H8O4040BHD	1
WATER	INACTIVE INGREDIENT	059QF0KO0R	1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 2 · 70 matching rows.

CONDITION AND ENHANCE SYSTEM TRAVEL-SIZE NON-SURGICAL
HYDROQUINONE, OCTINOXATE, AND ZINC OXIDE
CONDITION AND ENHANCE BLENDER Skin Lightener AND Blending
HYDROQUINONE
EDETATE DISODIUM
PPG-2 MYRISTYL ETHER PROPIONATE
TROLAMINE SALICYLATE
SODIUM LAURYL SULFATE
CETYL ALCOHOL
GLYCERIN
LACTIC ACID
ALPHA-TOCOPHEROL ACETATE
ASCORBIC ACID
SODIUM METABISULFITE
WATER
METHYLPARABEN
PROPYLPARABEN
BUTYLATED HYDROXYTOLUENE
PHENYL TRIMETHICONE
CONDITION AND ENHANCE CLEAR Skin Bleaching AND Corrector
BUTYLPARABEN
STEARYL ALCOHOL
CONDITION AND ENHANCE HEALTHY SKIN PROTECTION SPF 35
OCTINOXATE and ZINC OXIDE
OCTINOXATE
ZINC OXIDE
ISOPROPYL PALMITATE
ETHYLHEXYL STEARATE
CETOSTEARYL ALCOHOL
POLYSORBATE 60
C13-14 ISOPARAFFIN
LAURETH-7
DIETHANOLAMINE CETYL PHOSPHATE
PHENOXYETHANOL
ETHYLPARABEN
ISOBUTYLPARABEN
SODIUM HYDROXIDE
TRIETHOXYCAPRYLYLSILANE
CITRIC ACID MONOHYDRATE
CONDITION AND ENHANCE FOAMING

NDC Codes#

Product NDC, Package NDC table
Product NDC	Package NDC
62032-510	62032-510-60
62032-115	62032-115-10
62032-117	62032-117-36
62032-119	62032-119-10

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 3 · 98 matching rows.

Name, UNII, Kind table
Name	UNII	Kind
HYDROQUINONE	XV74C1N1AE	ACTIB
EDETATE DISODIUM	7FLD91C86K	IACT
PPG-2 MYRISTYL ETHER PROPIONATE	88R97D8U8A	IACT
TROLAMINE SALICYLATE	H8O4040BHD	IACT
SODIUM LAURYL SULFATE	368GB5141J	IACT
CETYL ALCOHOL	936JST6JCN	IACT
GLYCERIN	PDC6A3C0OX	IACT
LACTIC ACID	33X04XA5AT	IACT
ALPHA-TOCOPHEROL ACETATE	9E8X80D2L0	IACT
ASCORBIC ACID	PQ6CK8PD0R	IACT
SODIUM METABISULFITE	4VON5FNS3C	IACT
WATER	059QF0KO0R	IACT
METHYLPARABEN	A2I8C7HI9T	IACT
PROPYLPARABEN	Z8IX2SC1OH	IACT
BUTYLATED HYDROXYTOLUENE	1P9D0Z171K	IACT
PHENYL TRIMETHICONE	DR0K5NOJ4R	IACT
HYDROQUINONE	XV74C1N1AE	ACTIB
EDETATE DISODIUM	7FLD91C86K	IACT
BUTYLPARABEN	3QPI1U3FV8	IACT
STEARYL ALCOHOL	2KR89I4H1Y	IACT
SODIUM LAURYL SULFATE	368GB5141J	IACT
CETYL ALCOHOL	936JST6JCN	IACT
GLYCERIN	PDC6A3C0OX	IACT
LACTIC ACID	33X04XA5AT	IACT
ALPHA-TOCOPHEROL ACETATE	9E8X80D2L0	IACT
ASCORBIC ACID	PQ6CK8PD0R	IACT
SODIUM METABISULFITE	4VON5FNS3C	IACT
WATER	059QF0KO0R	IACT
METHYLPARABEN	A2I8C7HI9T	IACT
PROPYLPARABEN	Z8IX2SC1OH	IACT
BUTYLATED HYDROXYTOLUENE	1P9D0Z171K	IACT
OCTINOXATE	4Y5P7MUD51	ACTIB
ZINC OXIDE	SOI2LOH54Z	ACTIB
ISOPROPYL PALMITATE	8CRQ2TH63M	IACT
WATER	059QF0KO0R	IACT
ETHYLHEXYL STEARATE	EG3PA2K3K5	IACT
CETOSTEARYL ALCOHOL	2DMT128M1S	IACT
POLYSORBATE 60	CAL22UVI4M	IACT
C13-14 ISOPARAFFIN	E4F12ROE70	IACT
METHYLPARABEN	A2I8C7HI9T	IACT

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 14 · 811 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredient	IID ingredient	UNII	Dosage form / route	Potency	Maximum daily exposure	Match
EDETATE DISODIUM	EDETATE DISODIUM	7FLD91C86K	AEROSOL, FOAM / RECTAL		2 mg	Exact identifier — unii candidate 77 equally ranked IID candidates
CITRIC ACID MONOHYDRATE	CITRIC ACID MONOHYDRATE	2968PHW8QP	INJECTION, SOLUTION, CONCENTRATE / INTRAOCULAR		1 mg	Exact identifier — unii candidate 88 equally ranked IID candidates
EDETATE DISODIUM	EDETATE DISODIUM	7FLD91C86K	SOLUTION / NASAL	100 mg/100ml		Exact identifier — unii candidate 77 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	SOLUTION / DENTAL	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	SOLUTION / INTRATHECAL	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	EMULSION / ORAL	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION / INTRA-ARTERIAL	176 mg		Exact identifier — unii candidate 174 equally ranked IID candidates
EDETATE DISODIUM	EDETATE DISODIUM	7FLD91C86K	SUSPENSION/ DROPS / OPHTHALMIC		1 mg	Exact identifier — unii candidate 77 equally ranked IID candidates
EDETATE DISODIUM	EDETATE DISODIUM	7FLD91C86K	GEL / TOPICAL		24 mg	Exact identifier — unii candidate 77 equally ranked IID candidates
CITRIC ACID MONOHYDRATE	CITRIC ACID MONOHYDRATE	2968PHW8QP	INJECTION, SOLUTION / SUBCUTANEOUS		26 mg	Exact identifier — unii candidate 88 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION / INTRACARDIAC	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
CITRIC ACID MONOHYDRATE	CITRIC ACID MONOHYDRATE	2968PHW8QP	SOLUTION/ DROPS / OPHTHALMIC	0.05 %w/v		Exact identifier — unii candidate 88 equally ranked IID candidates
EDETATE DISODIUM	EDETATE DISODIUM	7FLD91C86K	INJECTION / SUBCUTANEOUS		6 mg	Exact identifier — unii candidate 77 equally ranked IID candidates
METHYLPARABEN	METHYLPARABEN	A2I8C7HI9T	GEL / TOPICAL		24 mg	Exact identifier — unii candidate 79 equally ranked IID candidates
GLYCERIN	GLYCERIN	PDC6A3C0OX	SOLUTION / RESPIRATORY (INHALATION)	5 %w/w		Exact identifier — unii candidate 75 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	GEL / TOPICAL		70 mg	Exact identifier — unii candidate 174 equally ranked IID candidates
CITRIC ACID MONOHYDRATE	CITRIC ACID MONOHYDRATE	2968PHW8QP	INJECTION, SOLUTION, CONCENTRATE / IRRIGATION		1 mg	Exact identifier — unii candidate 88 equally ranked IID candidates
METHYLPARABEN	METHYLPARABEN	A2I8C7HI9T	OINTMENT / TOPICAL		29 mg	Exact identifier — unii candidate 79 equally ranked IID candidates
GLYCERIN	GLYCERIN	PDC6A3C0OX	SOLUTION / NASAL	25 mg/1ml		Exact identifier — unii candidate 75 equally ranked IID candidates
PROPYLPARABEN	PROPYLPARABEN	Z8IX2SC1OH	SUSPENSION, EXTENDED RELEASE / ORAL		4 mg	Exact identifier — unii candidate 68 equally ranked IID candidates
PROPYLPARABEN	PROPYLPARABEN	Z8IX2SC1OH	CONCENTRATE / ORAL	2.5 mg/5ml		Exact identifier — unii candidate 68 equally ranked IID candidates
EDETATE DISODIUM	EDETATE DISODIUM	7FLD91C86K	POWDER, FOR SUSPENSION / ORAL		285 mg	Exact identifier — unii candidate 77 equally ranked IID candidates
CETOSTEARYL ALCOHOL	CETOSTEARYL ALCOHOL	2DMT128M1S	CAPSULE, EXTENDED RELEASE / ORAL	9.43 mg		Exact identifier — unii candidate 9 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	TABLET, EXTENDED RELEASE / ORAL		13 mg	Exact identifier — unii candidate 174 equally ranked IID candidates
PROPYLPARABEN	PROPYLPARABEN	Z8IX2SC1OH	ENEMA / RECTAL	0.02 %w/w		Exact identifier — unii candidate 68 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION, SOLUTION / PARENTERAL	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION, SOLUTION / INTRACAUDAL	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
CITRIC ACID MONOHYDRATE	CITRIC ACID MONOHYDRATE	2968PHW8QP	SOLUTION / AURICULAR (OTIC)	0.2 %w/v		Exact identifier — unii candidate 88 equally ranked IID candidates
PROPYLPARABEN	PROPYLPARABEN	Z8IX2SC1OH	CREAM / TOPICAL		6 mg	Exact identifier — unii candidate 68 equally ranked IID candidates
CETYL ALCOHOL	CETYL ALCOHOL	936JST6JCN	TABLET, FILM COATED, EXTENDED RELEASE / ORAL	59 mg		Exact identifier — unii candidate 20 equally ranked IID candidates
METHYLPARABEN	METHYLPARABEN	A2I8C7HI9T	FILM / BUCCAL		1 mg	Exact identifier — unii candidate 79 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	TABLET / ORAL		10 mg	Exact identifier — unii candidate 174 equally ranked IID candidates
GLYCERIN	GLYCERIN	PDC6A3C0OX	TABLET, COATED / ORAL	1 mg		Exact identifier — unii candidate 75 equally ranked IID candidates
METHYLPARABEN	METHYLPARABEN	A2I8C7HI9T	INJECTION, SOLUTION / PARENTERAL		30 mg	Exact identifier — unii candidate 79 equally ranked IID candidates
EDETATE DISODIUM	EDETATE DISODIUM	7FLD91C86K	DROPS / NASAL	0.1 mg/1ml		Exact identifier — unii candidate 77 equally ranked IID candidates
SODIUM METABISULFITE	SODIUM METABISULFITE	4VON5FNS3C	INJECTION, SOLUTION / INTRAMUSCULAR		96 mg	Exact identifier — unii candidate 43 equally ranked IID candidates
METHYLPARABEN	METHYLPARABEN	A2I8C7HI9T	INJECTION / EPIDURAL	1 mg		Exact identifier — unii candidate 79 equally ranked IID candidates
EDETATE DISODIUM	EDETATE DISODIUM	7FLD91C86K	SUSPENSION / ORAL		30 mg	Exact identifier — unii candidate 77 equally ranked IID candidates
GLYCERIN	GLYCERIN	PDC6A3C0OX	TABLET, CHEWABLE / ORAL		12 mg	Exact identifier — unii candidate 75 equally ranked IID candidates
SODIUM LAURYL SULFATE	SODIUM LAURYL SULFATE	368GB5141J	TABLET / SUBLINGUAL	1.1 mg		Exact identifier — unii candidate 42 equally ranked IID candidates
METHYLPARABEN	METHYLPARABEN	A2I8C7HI9T	SOLUTION / OPHTHALMIC	0.05 %w/w		Exact identifier — unii candidate 79 equally ranked IID candidates
SODIUM METABISULFITE	SODIUM METABISULFITE	4VON5FNS3C	LOTION / TOPICAL	0.2 %w/v		Exact identifier — unii candidate 43 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVERNOUS	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
EDETATE DISODIUM	EDETATE DISODIUM	7FLD91C86K	INJECTION, SOLUTION / SUBCUTANEOUS		2 mg	Exact identifier — unii candidate 77 equally ranked IID candidates
EDETATE DISODIUM	EDETATE DISODIUM	7FLD91C86K	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS		19 mg	Exact identifier — unii candidate 77 equally ranked IID candidates
SODIUM METABISULFITE	SODIUM METABISULFITE	4VON5FNS3C	SOAP / TOPICAL	0.36 %w/w		Exact identifier — unii candidate 43 equally ranked IID candidates
EDETATE DISODIUM	EDETATE DISODIUM	7FLD91C86K	INJECTION / INTRABURSAL	0.01 %w/v		Exact identifier — unii candidate 77 equally ranked IID candidates
GLYCERIN	GLYCERIN	PDC6A3C0OX	AEROSOL / TOPICAL	3 %w/w		Exact identifier — unii candidate 75 equally ranked IID candidates
BUTYLATED HYDROXYTOLUENE	BUTYLATED HYDROXYTOLUENE	1P9D0Z171K	INJECTION / INTRAVENOUS	NA		Exact identifier — unii candidate 32 equally ranked IID candidates
SODIUM LAURYL SULFATE	SODIUM LAURYL SULFATE	368GB5141J	TABLET, EFFERVESCENT / ORAL	1.5 mg		Exact identifier — unii candidate 42 equally ranked IID candidates
EDETATE DISODIUM	EDETATE DISODIUM	7FLD91C86K	SHAMPOO / TOPICAL	1 %w/w		Exact identifier — unii candidate 77 equally ranked IID candidates
SODIUM HYDROXIDE	SODIUM HYDROXIDE	55X04QC32I	INJECTION / INFILTRATION	ADJ PH		Exact identifier — unii candidate 174 equally ranked IID candidates
BUTYLPARABEN	BUTYLPARABEN	3QPI1U3FV8	LOTION / TOPICAL		4 mg	Exact identifier — unii candidate 15 equally ranked IID candidates
GLYCERIN	GLYCERIN	PDC6A3C0OX	SUSPENSION, EXTENDED RELEASE / ORAL		2000 mg	Exact identifier — unii candidate 75 equally ranked IID candidates
SODIUM METABISULFITE	SODIUM METABISULFITE	4VON5FNS3C	INJECTION / INTRA-ARTICULAR	0.2 %w/v		Exact identifier — unii candidate 43 equally ranked IID candidates
CITRIC ACID MONOHYDRATE	CITRIC ACID MONOHYDRATE	2968PHW8QP	TABLET, ORALLY DISINTEGRATING / ORAL		83 mg	Exact identifier — unii candidate 88 equally ranked IID candidates
SODIUM METABISULFITE	SODIUM METABISULFITE	4VON5FNS3C	INJECTION / INTRAVENOUS	27.5 %w/v		Exact identifier — unii candidate 43 equally ranked IID candidates
SODIUM LAURYL SULFATE	SODIUM LAURYL SULFATE	368GB5141J	PASTE, DENTIFRICE / DENTAL	1.4 %w/w		Exact identifier — unii candidate 42 equally ranked IID candidates
BUTYLATED HYDROXYTOLUENE	BUTYLATED HYDROXYTOLUENE	1P9D0Z171K	CAPSULE / ORAL		3 mg	Exact identifier — unii candidate 32 equally ranked IID candidates
CITRIC ACID MONOHYDRATE	CITRIC ACID MONOHYDRATE	2968PHW8QP	TABLET, CHEWABLE / ORAL	7 mg		Exact identifier — unii candidate 88 equally ranked IID candidates

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
5a4e3679-60da-4c02-b325-5b7aafafb375			5d843214-4ede-4bd5-a919-c8faca9ccade	2012-05-10	Warnings, Adverse reactions	Exact identifier spl id: 5a4e3679-60da-4c02-b325-5b7aafafb375 spl set id: 5d843214-4ede-4bd5-a919-c8faca9ccade

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.